|
|
| | benzo[d]oxazole-6-carboxylic acid Basic information |
| Product Name: | benzo[d]oxazole-6-carboxylic acid | | Synonyms: | benzo[d]oxazole-6-carboxylic acid;6-Benzoxazolecarboxylic acid;Benzoxazole-6-carboxylic Acid;1,3-Benzoxazole-6-carboxylic acid 97%;SB9;Serpin B9-IN-1;1,3-Benzoxazole-6-carboxylic acid, 10 mM in DMSO;1,3-Benzoxazole-6-carboxylic acid | | CAS: | 154235-77-5 | | MF: | C8H5NO3 | | MW: | 163.13 | | EINECS: | | | Product Categories: | | | Mol File: | 154235-77-5.mol | ![benzo[d]oxazole-6-carboxylic acid Structure](CAS/GIF/154235-77-5.gif) |
| | benzo[d]oxazole-6-carboxylic acid Chemical Properties |
| Melting point | 280-290 °C (sublm)(Press: 16 Torr) | | Boiling point | 350.1±15.0 °C(Predicted) | | density | 1.455±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | form | Solid | | pka | 3.60±0.30(Predicted) | | color | Light brown to brown |
| | benzo[d]oxazole-6-carboxylic acid Usage And Synthesis |
| Uses | 6-Benzoxazolecarboxylic Acid is a reactant used in the design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists. | | in vivo | Serpin B9-IN-1 (BTCA) inhibits bone metastasis (BM) in multiple tumor metastasis models. Serpin B9-IN-1 (50 mg/kg/d; ip; 14 d) effectively reduced the survival rate and metastasis proportion of metastatic cancer cells in the mouse bone metastasis model with LLC1-BM3 injected into the tail artery (CA)[1]. Serpin B9-IN-1 (300 μg/d; ip; 14 d) effectively delayed the average time to bone metastasis (BM) in the LLC1-BM3 cell group[1].
| Animal Model: | LLC1-BM3 Bone Metastatic Mouse Model by CA injections[1] | | Dosage: | 50 mg/kg | | Administration: | ip; followed after cancer cell injection, injection daily for 14 days | | Result: | Reduced the survival rate and metastasis proportion of metastatic cancer cells
|
| Animal Model: | LLC1-BM3-sr-ctrl Model in Mouse[1] | | Dosage: | 300 μg | | Administration: | ip; once daily for 14 days | | Result: | Delayed the mean time to occurrence of bone metastasis (BM), and lowered the burden of BM in LLC1-BM3-shSB9 cells group.
|
|
| | benzo[d]oxazole-6-carboxylic acid Preparation Products And Raw materials |
|